Bacterial Community-Acquired Pneumonia in Older Patients

Clinics in Geriatric Medicine

Volumn 23, Issue 3, 2007, Pages 515-534

  Donowitz, Gerald R ^a   Cox, Heather L ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFPODOXIME PROXETIL; DOXYCYCLINE; GEMIFLOXACIN; INFLUENZA VACCINE; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; VANCOMYCIN;

AGED; BACTERIAL PNEUMONIA; BLOOD DYSCRASIA; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFUSION; DELAYED DIAGNOSIS; DELIRIUM; DIZZINESS; DRUG FEVER; ELDERLY CARE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HALLUCINATION; HUMAN; INTERSTITIAL NEPHRITIS; LIVER TOXICITY; MALABSORPTION; MORBIDITY; MORTALITY; OTOTOXICITY; PHOTOSENSITIVITY; POPULATION RISK; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SOMNOLENCE; UNCONSCIOUSNESS; VISUAL DISORDER;

AGE FACTORS; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PNEUMONIA, BACTERIAL; PREVALENCE; RISK FACTORS; SURVIVAL RATE; WORLD HEALTH;

EID: 34447274530     PISSN: 07490690     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cger.2007.03.006     Document Type: Review

References (92)

1. Silvermanm M.E., Murray T.J., and Bryan C.S. The quotable Osler. Am Coll Physicians Obs (1998) 139
2. Minino A., Heron A.P., and Smith B.L. Deaths, preliminary data for 2004. National Vital Statistics Report 54 19 (2006) 1-52
3. Jackson M.L., Neuzil K.M., Thompson W.W., et al. The burden of community-acquired pneumonia in seniors: results of a population based study. Clin Infect Dis 39 (2004) 1651-1653
4. May D.S., Kelly J.J., Mendlein J.M., et al. Surveillance of major causes of hospitalization among the elderly 1988. MMWR CDC Surveill Summ 40 (1991) 7-21
5. Strausbaugh L.J. Emerging health care associated infections in the geriatric population. Emerg Infect Dis 7 (2001) 268-271
6. Gyetko M.R., and Toews G.B. Immunology of the aging lung. Clin Chest Med 14 (1993) 379-391
7. Meyer K.C. Aging. Proc Am Thorac Soc 2 (2005) 433-439
8. Janssens P., and Krause K.H. Pneumonia in the very old. Lancet Infect Dis 4 (2004) 112-124
9. Palmer L.B., Albulack K., Fields S., et al. Oral clearance and pathogenic oropharyngeal colonization of the elderly. Am J Respir Crit Care Med 164 (2001) 464-468
10. Kikuchi R., Watabe N., Konno T., et al. High incidence of silent aspiration in elderly patients with community acquired pneumonia. Am J Respir Crit Care Med 150 (1994) 251-253
11. Ho J.C., Chan K.N., Hu W.H., et al. The effect of aging on nasal mucocilliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med 163 (2001) 983-988
12. Meyer K.C. The role of immunity in susceptibility to respiratory infection in the aging lung. Respir Physiol 128 (2001) 23-31
13. Meyer K.C., Ershler W., Rosenthal N.S., et al. Immune dysregulation in the aging human lung. Am J Respir Crit Care Med 153 (1996) 1072-1079
14. Fraga M.F., Ballestar E., Paz M.F., et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci U S A 102 (2005) 10604-10609
15. Riquelme R., Torres A., El-Ebiary M., et al. Community-acquired pneumonia in the elderly: a multivariate analysis of risk factors and prognostic factors. Am J Respir Crit Care Med 154 (1996) 1450-1455
16. Ayers G.H., Altman L.C., and Fretwell M.D. Effect of decreased salivation and pH on the adherence of Klebsiella species to human buccal epithelial cells. Infect Immun 38 (1982) 179-182
17. Smaldone G.C. Deposition and clearance: unique problems in the proximal airways and oral cavity in the young and elderly. Respir Physiol 128 (2001) 33-38
18. Loeb M. Pneumonia in older persons. Clin Infect Dis 37 (2003) 1335-1339
19. Metlay J.P., Schulz R., Li H., et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 157 (1997) 1453-1459
20. Fernandez-Sabe N., Carratala J., Roson B., et al. Community-acquired pneumonia in very elderly patients: causative organism, clinical characteristics and outcomes. Medicine 82 (2003) 159-169
21. Granton J.T., and Grossman R.F. Community-acquired pneumonia in the elderly patient: clinical features, epidemiology, and treatment. Clin Chest Med 14 3 (1993) 537-553
22. Feldman C. Pneumonia in the elderly. Clin Chest Med 20 (1999) 563-573
23. Johnson J.C., Jayadevappa R., Baccash P.D., et al. Nonspecific presentation of pneumonia in hospitalized older people: age effect or dementia. J Am Geriatr Soc 48 (2000) 1316-1320
24. Marrie T.J., Haldane E.V., Faulkner R.S., et al. Community-acquired pneumonia requiring hospitalization: is it different in the elderly?. J Am Geriatr Soc 33 (1985) 671-680
25. Syrjala H., Broas M., Suramo I., et al. High resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 27 (1998) 358-363
26. Ruiz M., Ewig S., Marcos M.A., et al. Etiology, community-acquired pneumonia: impaired of age, comorbidity and severity. Am J Respir Crit Care Med 160 (1999) 397-405
27. Lim W.S., and Macfarland J.T. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. Eur Respir J 18 (2001) 362-368
28. Marik P.E., and Kaplan D. Aspiration pneumonia and dysphagia in the elderly. Chest 124 (2003) 328-336
29. Janssens J.P. Pneumonia in the elderly (geriatric) population. Curr Opin Pulm Med 11 (2005) 226-230
30. Fine M.J., Auble T.E., Yearly D.M., et al. A prediction rule to identify low risk patients with community-acquired pneumonia. N Eng J Med 336 (1997) 1248-1250
31. Fein A.M. Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin Infect Dis 28 (1999) 726-729
32. Lim W.S., Van der Eerden M.M., Laing R., et al. Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58 (2003) 377-382
33. Conte H.A., Chen Y.T., Mehal W., et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 106 (1999) 20-28
34. Seppa Y., Bloigu A., Honkanen P.O., et al. Severity assessment of lower respiratory tract infection in elderly patients in primary care. Arch Intern Med 161 (2001) 2709-2713
35. Arnold F.W., Ramirez J.A., McDonald L.C., et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 124 (2003) 121-124
36. Marras T.K., Gutierrez C., and Chan C.K. Applying a prediction rule to identify low-risk patients with community-acquired pneumonia. Chest 118 (2000) 1339-1343
37. Mandell L.A., Bartlett J.G., Dowel S.F., et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37 (2003) 1405-1433
38. Labarere J., Stone R.A., Obrosky S., et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia. Chest 131 (2007) 480-488
39. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Disease Society of America/America Thoracic Society census guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl 2 (2007) S27-S72
40. Donowitz G.R., Mandell G.L., et al. Acute pneumonia. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and practice of infectious diseases. 6th edition (2005), Elsevier Science, Philadelphia 819-845
41. Musher D.M., Montoya R., and Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum culture in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 39 (2004) 165-169
42. Fine M.J., Orloff J.J., Rihs J.D., et al. Evaluation of housestaff physicians' preparation and interpretation of sputum Gram stains for community-acquired pneumonia. J Gen Intern Med 6 (1991) 189-198
43. Garcia-Vasquez E., Marcos M.A., Mensa J., et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 164 (2007) 1807-1811
44. Bohte R., Van Furth R., and Van den Broek P.J. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 50 (1995) 543-547
45. Campbell S.G., Marrie T.J., Anstey R., et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 123 (2003) 1142-1150
46. Dominguez J., Gali N., Blanco S., et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 119 (2001) 243-249
47. Murdoch D.R., Laing T.R., and Mills G.D. Evaluation of a rapid immunochromatographics test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 39 (2001) 3495-3498
48. Smith M.D., Derrington P., Evans R., et al. Rapid diagnosis of bacteremic pneumococcal infection in adults by using the Binax now Streptococcus pneumoniae urine antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 41 (2003) 2810-2813
49. Ruf B., Schurmann D., Horbach I., et al. Frequency and diagnosis of Legionella pneumophilia: a 3 year prospective study with emphasis on application of urine detection. J of Infect Dis 162 (1990) 1341-1347
50. Niederman M.S., Mandell L.A., Anzueto A., et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 163 (2001) 1730-1754
51. Mandell L.A., Marrie T.J., Grossman R.F., et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 31 (2000) 383-421
52. British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults. Thorax 56 Suppl 4 (2001) iv1-iv64
53. Jacobs M.R., Bajaksouzian S., Windau A., et al. Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters. Clin Lab Med 24 (2004) 503-530
54. Garcia Vazquez E., Mensa J., Martinez J.A., et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 24 (2005) 190-195
55. Gleason P.P., Meehan T.P., Fine J.M., et al. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 159 (1999) 2562-2572
56. Stahl J.E., Barza M., DesJardin J., et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 159 (1999) 2576-2580
57. Tamaoki J. The effects of macrolides on inflammatory cells. Chest 125 (2004) 41S-50S
58. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 22 (1996) 387-394
59. Luna C.M., Vujacich P., Niederman M.S., et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 111 (1997) 676-685
60. Rello J., Gallego M., Mariscal D., et al. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 156 (1997) 196-200
61. Francis J.S., Doherty M.C., Lopatin U., et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis 40 (2005) 100-107
62. Fridkin S.K., Hageman J.C., Morrison M., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 352 (2005) 1436-1444
63. Gillet Y., Issartel B., Vanhems P., et al. Association between Staphylococcus aureus strains carrying the gene for Panton-Valentine leukocidin and highly lethal necrotizing pneumonia in young immunocompetent patients. Lancet 359 (2002) 753-759
64. Micek S.T., Dunne M., and Kollef M.H. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus. Chest 128 (2005) 3732-3738
65. Bernardo K., Pakulat N., Fleer S., et al. Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression. Antimicrob Agents Chemother 48 2 (2004) 546-555
66. Silverman J.A., Mortin L.I., VanPraagh A.D.G., et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191 (2005) 2149-2152
67. Shakeri-Nejad K., and Stahlmann R. Drug interactions during therapy with three major groups of antimicrobial agents. Expert Opin Pharmacother 7 (2006) 639-651
68. Cunha B.A. Antibiotic side effects. Med Clin North Am 85 (2001) 149-185
69. Lipsky B.A., and Baker C.A. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28 (1999) 352-364
70. Owens R.C., and Ambrose P.G. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41 (2005) S144-S157
71. Faulkner C.M., Cox H.L., and Williamson J.C. Unique aspects of antimicrobial use in older adults. Clin Infect Dis 40 (2005) 997-1004
72. Lam S., and Gomolin I.H. Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review. Pharmacotherapy 26 8 (2006) 1169-1174
73. Zuckerman J.M. Macrolides and ketolides: azithromycin, clarithromycin, telithromycin. Infect Dis Clin North Am 18 (2004) 621-649
74. Hung I.F.N., Wu A.K.L., Cheng V.C.C., et al. Fatal interaction between clarithromycin and colchicines in patients with renal insufficiency: a retrospective study. Clin Infect Dis 41 (2005) 291-300
75. Ketek (telithromycin) [package insert]. Bridgewater (NJ): Sanofi-Aventis US; 2007.
76. Clay K.D., Hanson J.S., Pope S.D., et al. Brief communication: severe hepatotoxicity of telithromycin. Three case reports and literature review. Ann Intern Med 144 (2006) 415-420
77. Information for health care professionals: gatifloxacin (marketed as Tequin), Food and Drug Administration. Available at: http://www.fda.gov/cder/drug/InfoSheets/HCP/gatifloxacinHCP.htm. Accessed March 7, 2006.
78. Park-Wyllie L.Y., Juurlink D.N., Kopp A., et al. Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354 (2006) 1352-1361
79. Fuller J.D., and Low D.E. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 41 (2005) 118-121
80. Pépin J., Saheb N., Coulombe M.A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Québec. Clin Infect Dis 41 (2005) 1254-1260
81. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449
82. Kaplan V., Clermont G., Griffin M.F., et al. Pneumonia, still the old man's friend. Arch Intern Med 103 (2003) 317-323
83. Metersky M.L., Tate J.P., Fine M.J., et al. Temporal trends in outcomes of older patients with pneumonia. Arch Intern Med 160 (2006) 3385-3391
84. Kaplan V., Angus D.C., and Griffin M.F. Hospitalized community acquired pneumonia in the elderly: age and sex-related pattern of care and outcome in the United States. Am J Respir Crit Care Med 165 (2002) 766-772
85. Korvula I., Sten M., and Makela P.H. Prognosis after community-acquired pneumonia in the elderly: a population-based 12 year follow-up study. Arch Intern Med 157 (1995) 1550-1555
86. Gross P.A., Hermogenes A.W., Sacks H.S., et al. The efficacy of influenza vaccine in elderly persons. Ann Intern Med 123 7 (1995) 518-527
87. Nichol K.L., Wuorenma J., and von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 158 (1998) 1769-1776
88. Spaude K.A., Abrutyn E., Kirchner C., et al. Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia. Arch Intern Med 167 (2007) 53-59
89. Jackson L.A., Neuzil K.M., Yu O., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 348 (2003) 1747-1755
90. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348 (2003) 1737-1746
91. Fisman D.N., Abrutyn E., Spaude K.A., et al. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 42 (2006) 1093-1101
92. Nuorti J.P., Butler J.C., Farley M.M., et al. Cigarette smoking and invasive pneumococcal disease. N Engl J Med 342 (2000) 681-689